Arix Bioscience PLC (ARIX) Artios Doses First Patient in Phase
1/2a Study of Pol? Inhibitor ART4215 28-Sep-2021 / 08:15 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS
Group. The issuer is solely responsible for the content of this
announcement.
-----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Artios Doses First Patient in Phase 1/2a Study of Pol? Inhibitor
ART4215
LONDON, 28 September 2021: Arix Bioscience plc ("Arix",
LSE:ARIX), a global venture capital company focused on investing in
and building breakthrough biotech companies, notes that its
portfolio company, Artios Pharma Limited, today announced it has
dosed the first patient in its Phase 1/2a study with its polymerase
theta (Pol?) inhibitor, ART4215.
Mark Chin, Managing Director at Arix, stated: "ART4215 is the
first selective, orally bioavailable, small molecule inhibitor of
the Pol? polymerase domain to enter the clinic. As early investors
and the largest shareholder in Artios, we are proud of the
Company's scientific leadership and its position as a global
powerhouse in DDR. Artios is a great example of how we can support
innovative and ambitious biotech companies."
The announcement can be accessed on Artios's website at:
https://www.artiospharma.com/ and full text of the announcement
from Artios is contained below.
[ENDS]
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Optimum Strategic Communications
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in and building breakthrough biotech companies around
cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
ARTIOS PHARMA PRESS RELEASE Artios Doses First Patient in Phase
1/2a Study of Pol? Inhibitor ART4215
-- Pol? inhibitor, ART4215, is the first selective, orally
bioavailable, small molecule inhibitor of the Pol? polymerase
domain to enter the clinic
-- Phase 1/2a study evaluating Pol? inhibitor, ART4215, in
patients with advanced or metastatic solid tumors
-- Pol? program developed using Artios's DDR-based platform and
small molecule drug discovery capabilities
-- Interim safety and tolerability data expected in 2022
-- Pol? inhibitor, ART4215, is Artios's second investigational
new drug to enter the clinic in 2021 alongwith ATR inhibitor,
ART0380
CAMBRIDGE, UK and NEW YORK, USA, 28 September 2021: Artios
Pharma Limited (Artios), a leading biotech company pioneering the
development of novel small molecule therapeutics that target the
DNA Damage Response process in order to treat patients suffering
from a broad range of cancers, announces it has dosed the first
patient in its Phase 1/2a study with its polymerase theta (Pol?)
inhibitor, ART4215. The Pol? project was originally in-licensed
from Cancer Research UK in 2016 as part of the initial formation of
Artios.
The open label, multi-center study will assess the safety,
tolerability, pharmacokinetics, and clinical activity of ART4215
administered orally as a monotherapy and in combination with other
anticancer medicines in patients with advanced or metastatic solid
tumors. The study will enroll up to 206 patients and will be
conducted at multiple oncology centers across the USA and Europe.
The trial is led by principal investigators Erika P. Hamilton,
M.D., Director of the Breast Cancer and Gynecologic Cancer Research
Program, Sarah Cannon Research Institute at Tennessee Oncology, and
Timothy Yap, M.B.B.S., Ph.D., Associate Professor of
Investigational Cancer Therapeutics and Medical Director of the
Institute for Applied Cancer Science at The University of Texas MD
Anderson Cancer Center. Interim safety and tolerability data is
expected in 2022. Full details can be found at
www.clinicaltrials.gov under the identifier NCT04991480.
Dr. Niall Martin, Chief Executive Officer at Artios, said: "The
initiation of our Phase 1/2a study is an important milestone for
Artios and the DNA Damage Response field in general, launching the
first evaluation of a specifically designed Pol? inhibitor in the
clinic. Pol? is an important tumor-specific DDR target which we
believe has the potential to exploit certain genetic
vulnerabilities of cancer cells with defective DNA repair
processes, while sparing healthy tissue. We have brought forward to
the clinic a new and exciting inhibitor class where preclinical
data shows the possible clinical utility that a potent, selective
Pol? inhibitor may have as a single agent in patients who have
progressed on PARP inhibitors, in combination with PARP inhibition
in PARPi naïve patients and in combination with DNA damaging
therapies such as ionizing radiation and cytotoxic chemotherapy.
The progress of ART4215 supports Artios's approach to leverage our
internal expertise in identifying promising new DDR targets,
developing novel molecules, working with our collaborators at
Cancer Research UK, and advancing these molecules into the clinic.
It has been a very productive year at Artios with the execution of
our USD153M Series C financing in July and now the expansion of our
clinical pipeline, building upon our ongoing clinical development
of ART0380, an ATR inhibitor, and our collaborations with Merck
KGaA and Novartis." Principal Investigator for the trial, Dr. Erika
P. Hamilton, Director of the Breast Cancer and Gynecologic Cancer
Research Program, Sarah Cannon Research Institute at Tennessee
Oncology, said: "I am encouraged by the preclinical data for
ART4215 that demonstrates the molecule's potential to address areas
of high unmet need such as overcoming de novo and acquired
resistance to PARP inhibitors and DNA damaging therapy. We look
forward to advancing these important studies for an entirely new
class of inhibitors for patients who need more effective treatment
options." ART4215 is the first selective, orally bioavailable,
small molecule inhibitor of the Pol? polymerase domain to enter the
clinic. Pol?, a DNA polymerase, is a tumor-specific DDR target
involved in microhomology mediated end joining (MMEJ) that is
overexpressed in many tumors and found in low levels in healthy
tissue. Extensive preclinical studies have demonstrated that
ART4215 has broad potential clinical utility, as described in
Artios's recent Nature Communications publication, Zatreanu et al.,
2021.
END
For more information, please contact:
Investor Contact:
Abid Ansari, Chief Financial Officer
E: Abid.Ansari@artiospharma.com
Media Contact:
LifeSci Advisors
Ligia Vela Reid
E: lvela-reid@lifesciadvisors.com
About Artios
Artios is a leading biotech company pioneering the development
of novel small molecule therapeutics that target the DDR process in
order to treat patients suffering from a broad range of cancers.
The Company is led by an experienced scientific and leadership team
with proven expertise in DDR drug discovery, including the
discovery and early development of the PARP inhibitor Olaparib. It
has a unique partnership with Cancer Research UK, and
collaborations with leading DNA repair researchers worldwide, such
as The Institute of Cancer Research (ICR), London, the Netherlands
Cancer Institute (NKI) and the Crick Institute, London. Artios is
building a pipeline of next-generation DDR programs to target hard
to treat cancers, including its ATR inhibitor, ART0380, in treating
DDR defective tumors, which is in a Phase 1/2a clinical study, and
the Pol? inhibitor ART4215 as a monotherapy and with combination
treatments. In December 2020, Artios entered into a collaboration
agreement with Merck KGaA, Darmstadt, Germany to identify and
develop precision oncology medicines targeting nucleases. Merck
KGaA, Darmstadt, Germany has the right to opt into exclusive
development and commercialization of compounds on up to eight
targets and Artios to receive up to USUSD860 million total
milestones per target. In April 2021, Artios entered a
collaboration with Novartis to identify DDR targets to use with
Novartis' proprietary radioligand therapies with Artios receiving a
USUSD20 million up-front payment in addition to near term research
funding to support the collaboration. Artios is eligible to receive
up to USD1.3 billion in discovery, development, regulatory and
sales-based milestones in addition to royalty payments. Artios has
raised USUSD320 million to date from investors and strategic
partners, including the USUSD153 million Series C financing
announced in July 2021. Artios is based at the Babraham Research
Campus in Cambridge, UK, with an office in New York City, USA.
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 123071
EQS News ID: 1236370
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1236370&application_name=news
(END) Dow Jones Newswires
September 28, 2021 03:15 ET (07:15 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2023 to Apr 2024
